ClinicalTrials.gg
RecruitingNCT07647783Updated Jun 15, 2026

A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets

A Phase 1 interventional study of SYH2072 Tablets and SYH2072 Placebo in Healthy Participants, sponsored by InnovStone Therapeutics Limited. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by InnovStone Therapeutics Limited (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2026, registered May 2026).
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

InnovStone Therapeutics Limited is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be fully informed about the study content, procedures, and potential adverse reactions, and voluntarily sign the written form (ICF) before the study;
  2. Sex: Male or female;
  3. Age: 18-55 years old (inclusive);
  4. in the range of 19 to 30 kg•m-2 [Body Mass Index (BMI) = weight/height2 (kg•m\^2)] (inclusive), with a body weight of no less than 50 kg for males (inclusive) and no less than 45 kg for females (inclusive);
  5. Participants are able to communicate well with the investigator and are able to complete the study in accordance with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergic diseases or allergic constitution (allergy to ≥ 3 drugs or foods);
  2. Use of drugs within 3 months prior to screening;
  3. Past and/or current medical conditions, including but not limited to diseases of the circulatory, hematologic or hematopoietic, respiratory, endocrine, urinary, digestive, nervous or psychiatric systems, infections, tumors, severe trauma, or any other disease that the investigator considers should be excluded or may interfere with the interpretation of the study results;
  4. Postural tachycardia (heart rate increase > 30 beats/minute upon standing) or postural hypotension (decrease in SBP ≥ 20mmHg or DBP ≥ 10mmHg upon standing) at screening;
  5. Have undergone major surgery within 6 months prior to screening, or plan to undergo major surgery during the study;
  6. Potassium ion level outside the normal range in clinical chemistry tests at screening, or serum creatinine > (ULN);
  7. Any one of the following at screening: (ALT), aspartate aminotransferase (AST), total (TBIL), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) > 1.2×ULN (one re-test within 1 week is allowed);
  8. Estimated (eGFR) \< 90mL/min/1.73 m2 at screening;
  9. Prolonged /QTc interval at screening (QTcF ≥ 450ms for males, ≥ 470ms for females);
  10. Positive for any of the following: , antibody, syphilis antibody, or antibody;
  11. Blood loss or blood donation exceeding 200mL within 3 months prior to screening (excluding menstruation for females), and/or donation within 2 weeks;
  12. Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or dietary supplements (including vitamins, health products, etc.) within 28 days prior to screening;
  13. History of drug abuse, and/or use of illicit drugs within 3 months prior to screening, and/or habitual use of any psychotropic drugs, including Chinese herbal medicines, and/or a positive urine drug screen;
  14. Average daily smoking of more than 5 cigarettes (or an equivalent amount of tobacco in e-cigarettes) within 3 months prior to screening, and/or unwilling to avoid using any tobacco products during the study;
  15. Regular alcohol consumption within 6 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360mL of 5% alcohol beer or 45mL of 40% alcohol spirits or 150mL of 12% alcohol wine), and/or inability to abstain from alcohol intake during the study, and/or a positive breath alcohol test;
  16. Excessive daily consumption of tea, coffee, and/or caffeinated beverages (8 cups or more, 1 cup = 250mL) within 1 month prior to screening, and/or unwilling to abstain from tea, coffee, and/or caffeinated foods, grapefruit and/or grapefruit juice, and/or poppy-containing products during the study;
  17. Having a fertility plan (including sperm or egg donation) from the time of signing the ICF until 3 months after the last dose, and/or unwilling to use an effective non-drug method of ;
  18. Participation in any clinical study within 3 months prior to screening;
  19. Participants who may be unable to complete the study for other reasons or who are deemed unsuitable for inclusion by the investigator.

    In addition to the above requirements, female participants who meet the following criteria will also be excluded:

  20. Pregnant or lactating women;
  21. Use of oral contraceptives within 28 days prior to screening;
  22. Use of long-acting estrogen and/or progestogen injections and/or implants within 6 months prior to screening; 23)Women of who have had unprotected sexual intercourse with a partner within 28 days prior to dosing.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Single Ascending Doses (SAD, Part A)

    In this part, 6 ascending dose cohorts (10 participants per cohort) will be studied. Within each cohort, participants will be randomized in a 4:1 ratio to receive either SYH2072 or placebo.

    Drug: SYH2072 Tablets · Drug: SYH2072 Placebo

  • Experimental
    Food Effect (FE, Part B)

    12 participants and single dose food effect cohort.

    Drug: SYH2072 Tablets

  • Experimental
    Experimental: Multiple Ascending Doses (MAD, Part C)

    In this part, 4 ascending dose cohorts (10 participants per cohort) will be studied. Within each cohort, participants will be randomized in a 4:1 ratio to receive either SYH2072 or placebo.

    Drug: SYH2072 Tablets · Drug: SYH2072 Placebo

Interventions

  • SYH2072 tablets will be administered as a single or multiple oral doses.

  • DrugSYH2072 Placebo

    SYH2072 placebo tablets will be administered as a single or multiple oral doses.

06

What researchers measure

Primary outcomes

  1. The rate of Adverse events

    The rate of Adverse events occur during the whole study

    Time frame: Through study completion, an average of 8 months

  2. The rate of normality or abnormality of electrocardiogram

    The rate of normality or abnormality of electrocardiogram during the whole study

    Time frame: Through study completion, an average of 8 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
Jun 15, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07647783
Responsible party
Sponsor
First posted
Jun 15, 2026
Start date
Jan 15, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jun 15, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
+86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYH2072

Start the discussion